drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
An anti-CD33 antibody–drug conjugate that targets CD33-positive myeloblasts and delivers the cytotoxic agent calicheamicin to induce DNA double-strand breaks.
nci_thesaurus_concept_id
C1806
nci_thesaurus_preferred_term
Gemtuzumab Ozogamicin
nci_thesaurus_definition
A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin. In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)
drug_mesh_term
Gemtuzumab Ozogamicin
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Anti-CD33 monoclonal antibody–drug conjugate that binds CD33 on myeloblasts, is internalized, and releases the cytotoxic payload calicheamicin in lysosomes; calicheamicin binds the DNA minor groove and induces double‑strand breaks, leading to apoptosis of CD33-positive cells.
drug_name
Gemtuzumab ozogamicin
nct_id_drug_ref
NCT05558124